Samalizumab
Based on 1 publication(s) in Google Scholar
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 1073059-33-2
- Molecular Weight:144.84 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Samalizumab
More
Biological Activity
Human IgG2 kappa
Human
CD220/Insulin Receptor
Samalizumab is rationally engineered with an Ig G2/G4 constant region to minimize effector function and preserve immune cell subsets. Samalizumab is a first-in-class, recombinant humanized anti-CD200 mAb, engineered to ablate effector function, that specifically binds to the immune checkpoint CD200, blocks receptor engagement and signaling and antagonizes CD200-driven immune suppression, thereby mount an anti-tumor immune response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized CD200 Protein (His Tag), Human can bind Samalizumab. The EC50 for this effect is 1.53 ng/mL.
Chemical Information
-
CAS No. 1073059-33-2
-
Appearance Liquid
-
Molecular Weight 144.84 kDa
-
Color Colorless to light yellow
-
SMILES
[Samalizumab]
-
Synonyms
ALXN 6000
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Monocytes from patients with myelodysplastic syndrome inhibit natural killer cell-mediated antitumor function through the CD200/CD200R pathway. [Abstract]2025 Apr 16:152:114394. PMID: 40049088
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz